AU3909597A - Dosage form for providing ascending dose of drug - Google Patents

Dosage form for providing ascending dose of drug

Info

Publication number
AU3909597A
AU3909597A AU39095/97A AU3909597A AU3909597A AU 3909597 A AU3909597 A AU 3909597A AU 39095/97 A AU39095/97 A AU 39095/97A AU 3909597 A AU3909597 A AU 3909597A AU 3909597 A AU3909597 A AU 3909597A
Authority
AU
Australia
Prior art keywords
dosage form
drug
ascending dose
providing ascending
providing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39095/97A
Other languages
English (en)
Inventor
Atul D. Ayer
Lawrence G. Hamel
Andrew Lam
Padmaja Shivanand
Jeri D Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21814183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU3909597(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of AU3909597A publication Critical patent/AU3909597A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AU39095/97A 1996-08-16 1997-08-08 Dosage form for providing ascending dose of drug Abandoned AU3909597A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2328696P 1996-08-16 1996-08-16
US60023286 1996-08-16
PCT/US1997/013816 WO1998006380A2 (en) 1996-08-16 1997-08-08 Dosage form for providing ascending dose of drug

Publications (1)

Publication Number Publication Date
AU3909597A true AU3909597A (en) 1998-03-06

Family

ID=21814183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39095/97A Abandoned AU3909597A (en) 1996-08-16 1997-08-08 Dosage form for providing ascending dose of drug

Country Status (13)

Country Link
EP (1) EP0957899B1 (enExample)
JP (1) JP4393587B2 (enExample)
CN (2) CN100484518C (enExample)
AT (1) ATE234602T1 (enExample)
AU (1) AU3909597A (enExample)
CA (1) CA2263558A1 (enExample)
CY (1) CY2475B1 (enExample)
DE (1) DE69720055T2 (enExample)
DK (1) DK0957899T3 (enExample)
ES (1) ES2194210T3 (enExample)
PT (1) PT957899E (enExample)
WO (1) WO1998006380A2 (enExample)
ZA (1) ZA977254B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
EP1690531A3 (en) * 1996-09-30 2010-01-20 Alza Corporation Dosage form and method for administering drug
PT932388E (pt) * 1996-09-30 2006-07-31 Alza Corp Forma de dosagem e metodo para administracao de farmacos
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP0946151B1 (en) * 1996-11-25 2006-05-10 Alza Corporation Ascending-dose dosage form
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
KR100890537B1 (ko) * 1998-06-03 2009-03-27 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
AU2012232984B2 (en) * 1998-06-03 2015-10-29 Alza Corporation Methods and devices for providing prolonged drug therapy
KR100827254B1 (ko) * 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
CN1209098C (zh) * 1998-06-03 2005-07-06 阿尔扎有限公司 提供药物长效治疗的方法和装置
AU2004200938B2 (en) * 1998-06-03 2006-09-14 Alza Corporation Methods and devices for providing prolonged drug therapy
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
KR20020072290A (ko) * 2000-01-20 2002-09-14 델시스 파머수티컬 코포레이션 다단계 약물 투여 형태
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
JP4500679B2 (ja) * 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
WO2004041255A1 (en) * 2002-10-31 2004-05-21 Alza Corporation Dosage form providing ascending release of liquid formulation
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180360817A1 (en) * 2015-12-31 2018-12-20 Cadila Healthcare Limited Extended release osmotic dosage form comprising high methylphenidate hydrochloride load
EP3501504A1 (en) 2017-12-22 2019-06-26 Pharmacia Polonica sp. z o.o. Modified release tablet of paliperidone and a process for the preparation thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
GB2206046B (en) * 1987-06-25 1991-04-03 Alza Corp Multi-unit delivery system
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation

Also Published As

Publication number Publication date
WO1998006380A2 (en) 1998-02-19
WO1998006380A3 (en) 1998-05-14
DE69720055D1 (de) 2003-04-24
ATE234602T1 (de) 2003-04-15
CN101518517A (zh) 2009-09-02
CN100484518C (zh) 2009-05-06
CN101518517B (zh) 2014-11-26
JP2000516610A (ja) 2000-12-12
EP0957899B1 (en) 2003-03-19
HK1021886A1 (zh) 2000-07-14
HK1137355A1 (zh) 2010-07-30
ZA977254B (en) 1998-05-11
ES2194210T3 (es) 2003-11-16
DK0957899T3 (da) 2003-04-22
PT957899E (pt) 2003-07-31
JP4393587B2 (ja) 2010-01-06
CY2475B1 (en) 2005-06-03
CN1228691A (zh) 1999-09-15
DE69720055T2 (de) 2003-09-11
EP0957899A2 (en) 1999-11-24
CA2263558A1 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
ZA977254B (en) Dosage form for providing ascending dose of drug.
AU5267698A (en) Ascending-dose dosage form
AU4801497A (en) Dosage form and method for administering drug
HRP960300B1 (en) Inhaler for administration of blister-packed medicaments
AU1534699A (en) Osmotic dosage form comprising first and second coats
AU5945296A (en) Medicament for nasal administration
WO1994027589A3 (en) Antidepressant dosage form
AU6060896A (en) Oral 1alpha-hydroxyprevitamin D
ATE166575T1 (de) Tramadolsalz enthaltende arzneimittel mit verzögerter wirkstofffreitsetzung
IE821214L (en) Medicament
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
AU2084801A (en) Antiviral medication
RO116771B1 (ro) Metodă pentru prevenirea sau tratamentul dependenţei, toleranţei sau abuzului de benzodiazepine
AU2939897A (en) Administration of histamine for therapeutic purposes
AU6934691A (en) Transdermal administration of zwitterionic drugs
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
AU5805096A (en) Transdermal therapeutic system (TTS) for the administration of testosterone
MX9803478A (es) Una composicion farmaceutica para el tratamiento de enfermedades autoinmunes.
IL117809A (en) Medical patch for rate-controlled transdermal administration of risperidone
IL116615A0 (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole and of salts thereof
MX9605190A (es) Forma de dosis efectiva para farmacos antiepilepticos.
ZA977873B (en) Dosage form and method for administering drug.
GB9301351D0 (en) An improved method of drug administration
AU4391196A (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts
GB8808995D0 (en) Apparatus for oral administration of medicament